https://www.selleckchem.com/pr....oducts/pd-1-pd-l1-in
Primary prevention of hormonally insensitive breast cancers remains an important clinical need and repurposing existing low-toxicity drugs represents a low-cost, efficient strategy for meeting this goal. This study targeted the cholesterol pathway using fluvastatin, a cholesterol-lowering drug, and aspirin, an AMPK activator that acts as a brake in the cholesterol pathway, in a transgenic mouse model of triple-negative breast cancer (TNBC). Using SV40C3 TAg mice, the efficacy and mechanism of fluvastatin, aspirin, or both
Like
Comment
Share
